CT-guided interstitial brachytherapy of inoperable non-small cell lung cancer

Wang, Zhongmin; Lu, Junxi; Liu, Tao; Chen, Kemin; Huang, Gang; Liu, Fenju

doi:10.1016/j.lungcan.2011.03.006

Cited by 45 publications

(26 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was consistent with previous studies. [44][45][46] Additionally, group A showed no surgery-related lethal hemoptysis, esophagotracheal fistula, or life-threatening morbidity. There were 5 patients with pneumothorax after implantation.…”

Section: Discussionmentioning

confidence: 90%

125I Brachytherapy in Locally Advanced Non-Small Cell Lung Cancer after Progression of Concurrent Radiochemotherapy

Xiang

Zhang

2016

Brachytherapy

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 90%

125I Brachytherapy in Locally Advanced Non-Small Cell Lung Cancer after Progression of Concurrent Radiochemotherapy

Xiang

Zhang

2016

Brachytherapy

View full text Add to dashboard Cite

“…This was consistent with previous studies. 44–46 Additionally, group A showed no surgery-related lethal hemoptysis, esophagotracheal fistula, or life-threatening morbidity. There were 5 patients with pneumothorax after implantation.…”

Section: Discussionmentioning

confidence: 94%

125I Brachytherapy in Locally Advanced Nonsmall Cell Lung Cancer After Progression of Concurrent Radiochemotherapy

Xiang

Liu

et al. 2015

Medicine

View full text Add to dashboard Cite

To investigate the safety and effectiveness of computed tomography (CT)-guided 125I seed implantation for locally advanced nonsmall cell lung cancer (NSCLC) after progression of concurrent radiochemotherapy (CCRT).We reviewed 78 locally advanced NSCLC patients who had each one cycle of first-line CCRT but had progressive disease identified from January 2006 to February 2015 at our institution. A total of 37 patients with 44 lesions received CT-guided percutaneous 125I seed implantation and second-line chemotherapy (group A), while 41 with 41 lesions received second-line chemotherapy (group B).Patients in group A and B received a total of 37 and 41 first cycle of CCRT treatment. The median follow-up was 19 (range 3–36) months. After the second treatment, the total response rate (RR) in tumor response accounted for 63.6% in group A, which was significantly higher than that of group B (41.5%) (P = 0.033). The median progression-free survival time (PFST) was 8.00 ± 1.09 months and 5.00 ± 0.64 months in groups A and B (P = 0.011). The 1-, 2-, and 3-year overall survival (OS) rates for group A were 56.8%, 16.2%, and 2.7%, respectively. For group B, OS rates were 36.6%, 9.8%, and 2.4%, respectively. The median OS time was 14.00 ± 1.82 months and 10.00 ± 1.37 months for groups A and B, respectively (P = 0.059). Similar toxicity reactions were found in both groups. Tumor-related clinical symptoms were significantly reduced and the patients’ quality of life was obviously improved.CT-guided 125I seed implantation proved to be potentially beneficial in treating localized advanced NSCLC; it achieved good local control rates and relieved clinical symptoms without increasing side effects.

show abstract

“…125 I seed implantation is a minimally invasive treatment for tumors that has been rapidly developed in the past decade and has been listed as a treatment for prostate cancer (26). 125 I seeds are implanted into tumors and continuously generate low-energy gamma-rays to kill tumor cells in a similar manner to multiple hyperfractionated radiotherapy, which can prevent the accelerated repopulation of tumor cells (27,28). In addition, low radiation dose rates can induce reoxygenation and increase blood flow in hypoxic tumors, thus producing a radiation-induced bystander effect to kill tumor cells, which can overcome uneven distribution of radiation doses (27,28).…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of CT‑guided 125I brachytherapy in elderly patients with non‑small cell lung cancer

et al. 2020

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) has become the most common cancer type and the leading cause of cancer-associated mortality worldwide. The aim of the present retrospective study was to evaluate the efficacy and safety of computed tomography (CT)-guided 125 I brachytherapy alone in elderly patients with NSCLC. A total of 26 elderly patients with NSCLC stage I-III who had an inoperable lesion or progressive disease following radio-chemotherapy were treated with CT-guided 125 I seed implantation for lung lesions and included in the present study. The prescribed dose of 125 I brachytherapy was 80-140 Gy, and dosimetric verification was performed immediately after the procedure. The response rate (RR) and local control rate (LCR) were analyzed according to the Response Evaluation Criteria in Solid Tumors (version 1.1). Survival was estimated using the Kaplan-Meier method. Safety and complications were also documented. All patients were aged 65-85 years (median age, 77 years) and successfully completed the procedure, and the median follow-up time was 9.4 months (range, 3-31 months). After a 6-month follow-up, for pulmonary lesions, complete response (CR) was achieved in 11 (42.3%) cases, partial response in 9 (34.6%) cases, stable disease in 4 (15.4%) cases and progressive disease in 2 (7.7%) cases. The 6-month RR and LCR were 76.9 (20/26) and 92.3% (24/26), respectively. The mean overall survival (OS) time was 11.7±7.6 months and the 0.5-and 1-year OS rates were 90.1 and 73.3%, respectively. Tumor-related symptoms in patients were significantly alleviated following the procedure. No severe complications occurred during and after the procedure of 125 I seed implantation. In conclusion, CT-guided 125 I brachytherapy is a feasible, effective and safe therapy and may be considered as an alternative option to surgery and radiotherapy for elderly patients with NSCLC.

show abstract

CT-guided interstitial brachytherapy of inoperable non-small cell lung cancer

Cited by 45 publications

References 24 publications

125I Brachytherapy in Locally Advanced Non-Small Cell Lung Cancer after Progression of Concurrent Radiochemotherapy

125I Brachytherapy in Locally Advanced Non-Small Cell Lung Cancer after Progression of Concurrent Radiochemotherapy

125I Brachytherapy in Locally Advanced Nonsmall Cell Lung Cancer After Progression of Concurrent Radiochemotherapy

Efficacy and safety of CT‑guided 125I brachytherapy in elderly patients with non‑small cell lung cancer

Contact Info

Product

Resources

About